June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
June 25th 2025
New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.
June 12th 2025
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
June 12th 2025
Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.
May 31st 2025
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Link Between Lung Dysfunction And Cognitive Decline in Long COVID Patients
November 27th 2024New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential treatment strategies.
Read More
What We Know But Still Have to Learn About Long COVID
Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Read More
Addressing the Diagnostic Gap in Long COVID Care
Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.
Read More
Day 1 Recap from CDC ACIP Meeting: COVID, Pneumococcal, Influenza, and RSV Vaccine Recommendations
October 24th 2024Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.
Read More
Evaluating the Efficacy of Paxlovid in High-Risk Patients with Pre-Existing Immunity
October 22nd 2024John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Watch
Original COVID-19 Strain Greatly Increased Risk for Heart Attack, Stroke, Death
October 11th 2024A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.
Read More
The Underuse of COVID-19 Antiviral Treatments in Older Adults
October 11th 2024Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.
Read More
Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 Variants
October 4th 2024Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Watch
NFID Survey: Fewer Than 1 in 5 Americans Are Concerned About Respiratory Viruses
September 26th 2024The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.
Read More
Reassessing COVID-19 Treatments: Nirmatrelvir/Ritonavir and Molnupiravir Against New Variants
September 19th 2024Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.
Read More
2 Commerce Drive
Cranbury, NJ 08512